Early start. Extra Years of Control with Galvus®Met

Early start. Extra Years of Control with Galvus^®Met

The VERIFY study redefined durability in T2DM management

T2DM is a progressive disease, causing progressive deterioration of glycaemic control over time with monotherapy alone.¹ While monotherapy is efficacious, it is not durable.¹

The landmark VERIFY trial showed that initiating therapy with vildagliptin + metformin (Galvus^®Met) achieved additional 2 years of glycaemic control versus stepwise therapy.2^*

Initiating treatment-naïve patients with Galvus^®Met can delay the time to treatment intensification by providing >5 years of glycaemic control without tolerability concerns.^2*

^*Standard-of-care that includes initial metformin monotherapy followed by vildagliptin + metformin combination therapy after monotherapy failure
^†Treatment failure defined as HbA1c ≥ 7% twice consecutively, 13 weeks apart.
²A multicentre, randomised, double-blind two arm, parallel-group study consisting of a screening visit, a 3-week run-in period with a primary defined
‘failure’ threshold over a 5-year treatment period during which patients’ treatment is consecutively intensified, if clinically indicated.

Abbreviations:
CI, confidence interval; HbA1c, glycated haemoglobin; HR, hazard ratio; RR, risk reduction; VERIFY; Vildagliptin Efficacy in combination with metfoRmIn For earlY treatment of type 2 diabetes.

References:

1. Turner RC, et al. JAMA. 1999;281(21):2005-2012.
2. Matthews DR, et al. Lancet. 2019;394(10208):1519-1529.

Novartis Healthcare Philippines, Inc.
5/F Ayala North Exchange Building Tower One, Ayala Ave. cor. Salcedo & Amorsolo Street,
San Lorenzo, Makati City 1123 Philippines

This material is supported by Novartis.
The content is intended for Healthcare Professionals for medical educational purposes only.
Novartis does not engage in the promotion of unregistered products or unapproved indications.
Please consult local Prescribing Information for registration/product license details.
For suspected adverse drug reaction, kindly report through [email protected] or call +63 2 7368 7777.

For Healthcare Professionals Only | Full Prescribing Information Available Upon Request

FOR HEALTHCARE PROFESSIONALS ONLY
FA-11540476-Oct2025-Oct2027

×

Medical Information Request

Ask Speakers